Paolo Augusto Paoletti
Director/Board Member presso GENMAB A/S
Patrimonio netto: 631 863 $ in data 31/03/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Deirdre Connelly | F | 63 | 14 anni | |
| Jan van de Winkel | M | 63 | 25 anni | |
| Emma Walmsley | F | 55 | 14 anni | |
| Edward F. Patz | M | - |
Grid Therapeutics LLC
 Grid Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Grid Therapeutics LLC develops and research cancer therapeutics to develop human derived antibodies. Its pipeline drugs include GT103 recombinant complement factor H monoclonal antibody and GT-20(x) recombinant monoclonal antibody. The company was founded by Edward F. Patz, Jr., Michael John Campagna and Elizabeth B. Gottlin and is headquartered in Chapel Hill, NC. | - |
| Phil Thomson | M | - | 13 anni | |
| Anthony Pagano | M | 46 | 17 anni | |
| Tahamtan Ahmadi | M | 51 | 7 anni | |
| Jeannette Potts | M | 62 | 5 anni | |
| Martine van Vugt | M | 71 | 23 anni | |
| Elizabeth O'Farrell | F | 59 | 2 anni | |
| Marisol Peron | F | - | 5 anni | |
| Howard Davis | M | - |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | 2 anni |
| Pernille Erenbjerg | F | 57 | 9 anni | |
| Rolf K. Hoffmann | M | 64 | 8 anni | |
| John Duncan Higgons | M | 69 |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Urs Rohner | M | 65 | 9 anni | |
| Thomas L. Patz | M | 63 |
Grid Therapeutics LLC
Grid Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Grid Therapeutics LLC develops and research cancer therapeutics to develop human derived antibodies. Its pipeline drugs include GT103 recombinant complement factor H monoclonal antibody and GT-20(x) recombinant monoclonal antibody. The company was founded by Edward F. Patz, Jr., Michael John Campagna and Elizabeth B. Gottlin and is headquartered in Chapel Hill, NC. | - |
| Judith Klimovsky | M | 67 | 7 anni | |
| Mijke Zachariasse | M | 51 | 5 anni | |
| Christopher Cozic | M | 46 | - | |
| Anthony Mancini | M | 53 | 4 anni | |
| Ruth du Moulin | F | - | 4 anni | |
| Ezra Cohen | M | - |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Martin Schultz | M | 49 | 2 anni | |
| Takahiro Hamatani | M | 50 | 2 anni | |
| Frannie DeFranco | F | - | 14 anni | |
| María Cristina de Luna Basagoiti | F | - | 14 anni | |
| David N. Cook | M | 66 | 4 anni | |
| Richard Parker | M | - |
Grid Therapeutics LLC
Grid Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Grid Therapeutics LLC develops and research cancer therapeutics to develop human derived antibodies. Its pipeline drugs include GT103 recombinant complement factor H monoclonal antibody and GT-20(x) recombinant monoclonal antibody. The company was founded by Edward F. Patz, Jr., Michael John Campagna and Elizabeth B. Gottlin and is headquartered in Chapel Hill, NC. | - |
| Kevin A. Schulman | M | - |
Grid Therapeutics LLC
Grid Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Grid Therapeutics LLC develops and research cancer therapeutics to develop human derived antibodies. Its pipeline drugs include GT103 recombinant complement factor H monoclonal antibody and GT-20(x) recombinant monoclonal antibody. The company was founded by Edward F. Patz, Jr., Michael John Campagna and Elizabeth B. Gottlin and is headquartered in Chapel Hill, NC. | - |
| Brian Champion | M | - |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Tracey Adamson | F | - |
Biomed Ltd.
 Biomed Ltd. Pharmaceuticals: MajorHealth Technology Biomed Ltd. manufactures pharmaceutical products. The company is headquartered in Auckland, New Zealand. | - |
| Matthew Foy | M | - |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Victoria Whyte | F | - | 15 anni | |
| Todd Shegog | M | 59 | 5 anni | |
| Birgitte Stephensen | F | 63 | 22 anni | |
| Graeme Scott Hawkins | M | - |
Biomed Ltd.
Biomed Ltd. Pharmaceuticals: MajorHealth Technology Biomed Ltd. manufactures pharmaceutical products. The company is headquartered in Auckland, New Zealand. | - |
| Andrew Carlsen | M | - | 5 anni | |
| Samuel Cameron Williams | M | 55 |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Mette Agger | F | 59 |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Anders Gersel Pedersen | M | 73 | 21 anni | |
| Mario Corso | M | - | 4 anni | |
| Anita Kidgell | F | - | 16 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Mats Gunnar Pettersson | M | 78 | 7 anni | |
| Philip Hampton | M | 70 | 4 anni | |
| Michael A. Foley | M | 62 | 9 anni | |
| Thomas Mount | M | - | 7 anni | |
| Frank Lee | M | 56 | 3 anni | |
| Daniel John Bruno | M | 45 | - | |
| Rachel Curtis Gravesen | F | 55 | 8 anni | |
| Judy Lewent | F | 75 | 10 anni | |
| Daniel Bach | M | - |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Michael K. Bauer | M | 60 | 14 anni | |
| Selwyn Vickers | M | 64 | 1 anni | |
| Jonathan Peacock | M | 66 | 1 anni | |
| Hans Henrik Munch-Jensen | M | 64 | 8 anni | |
| Wayne Frederick | M | 52 | 2 anni | |
| Anjali Bansal | F | 53 | 6 anni | |
| Michal Silverberg | F | 48 | 3 anni | |
| Balbir Kelly Bisla | F | - | 4 anni | |
| Ravi Rao | M | 55 | 7 anni | |
| Patrick F. Kelly | M | 60 | 6 anni | |
| Peter Kolchinsky | M | 47 | 3 anni | |
| Jing Ulrich | F | 56 | - | |
| Steve Hall | M | 69 | 11 anni | |
| Stacey Cartwright | F | 60 | 5 anni | |
| Jean-Pierre Garnier | M | 75 | 8 anni | |
| H. Culp | M | 60 | 9 anni | |
| Burt Malkiel | M | 90 | 11 anni | |
| Ian Maurice Gray Prosser | M | 81 | 9 anni | |
| Robert Wilson | M | 81 | 11 anni | |
| Lynn Elsenhans | F | 68 | 10 anni | |
| Christopher Gent | M | 75 | 11 anni | |
| James Murdoch | M | 51 | 3 anni | |
| Crispin Davis | M | 75 | 10 anni | |
| Robert Carr | M | - | 26 anni | |
| Thomas Wiggans | M | 72 | 2 anni | |
| Timothy Clackson | M | 58 | 4 anni | |
| Christopher Viehbacher | M | 64 | 20 anni | |
| Simon Dingemans | M | 61 | 8 anni | |
| Julian Heslop | M | 70 | 13 anni | |
| Gerardus Johannes Wijers | M | 74 | 3 anni | |
| Cedrik M. Britten | M | 49 | 5 anni | |
| Tonya Williams | F | 50 | 1 anni | |
| Filippo Lanzi | M | - | 9 anni | |
| Jay Green | M | 52 | 6 anni | |
| Jing Ji | M | 54 | 4 anni | |
| Hu Li | M | 59 | 19 anni | |
| Jane Hughes | M | 50 | 3 anni | |
| Min Li | M | 62 | 6 anni | |
| Michael Owen | M | 73 | 9 anni | |
| Michael G. Moore | M | - |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Atul Pande | M | 69 | 7 anni | |
| Anne Michelle Whitaker | F | 56 | 3 anni | |
| Martin Andrews | M | 61 | 10 anni | |
| Elyse G. Seltzer | M | 59 | 6 anni | |
| Abid Ansari | M | 46 | 5 anni | |
| Kim Sablich | F | 55 | 8 anni | |
| Adrian Rawcliffe | M | 52 | 17 anni | |
| Pearl Shirley Huang | M | 66 | 2 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Regno Unito | 55 | 55.00% |
| Danimarca | 25 | 25.00% |
| Stati Uniti | 19 | 19.00% |
| Nuova-Zelanda | 2 | 2.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Paolo Augusto Paoletti
- Contatti personali
